Compare Opendoor Technologies Inc (OPEN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Opendoor Technologies (OPEN) trades at $4.48, down 0.44% on the day, with a bearish technical outlook and mixed fundamental signals. The stock shows a low price-to-sales ratio of 0.93 but suffers from significant losses, with a net income margin of -35.25% and negative ROE of -173.61%. Recent earnings have been volatile, missing estimates in Q1 2026. Cash flow improved in 2025 with net cash flow of $538 million, though revenue declined to $4.37 billion. News highlights include the upcoming Q2 2026 earnings report and strategic shifts like closing India operations to focus on AI.

The outlook remains challenging due to persistent losses and a tough housing market, but cost-cutting and operational adjustments under new CEO Kaz Nejatian offer potential for margin improvement. Risks include high debt, competitive pressure from Zillow, and interest rate sensitivity. Analyst sentiment is cautious with 65.39% hold ratings, reflecting uncertainty about sustainable profitability. Investors should weigh the low valuation against execution risks in a volatile sector.

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.